Bavarian Nordic A/S (OTCMKTS:BVNRY) Sets New 52-Week High at $9.14

Bavarian Nordic A/S (OTCMKTS:BVNRY)’s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $9.14 and last traded at $9.14, with a volume of 4131 shares changing hands. The stock had previously closed at $8.91.

Bavarian Nordic A/S Trading Up 2.6 %

The firm has a fifty day moving average price of $8.41 and a 200 day moving average price of $7.92. The firm has a market capitalization of $2.14 billion, a price-to-earnings ratio of 14.14 and a beta of 1.67.

Bavarian Nordic A/S (OTCMKTS:BVNRY) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.07) EPS for the quarter. Bavarian Nordic A/S had a return on equity of 15.54% and a net margin of 14.74%. The business had revenue of $121.08 million during the quarter. As a group, equities analysts predict that Bavarian Nordic A/S will post 0.52 EPS for the current fiscal year.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.